by Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Clin Infect Dis, October 2006, 43(7):917-24. Epub 2006 Aug 28.
Summary: During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.